Concepedia

Author

Xiaoyan Chu

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Chu Xiao-yan, Chu Xiaoyan, Discovery, X Chu, X Y Chu, X. Chu, Xiao-Yan CHU, Xiao-Yan Chu, Xiao-yan Chu, Xiaoyan Chu

123

Publications

10.1K

Citations

47

H-Index

82

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of WashingtonGilead Sciences (United States)The University of TokyoBiogen (United States)
XC

About

Xiaoyan Chu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

16

997

2

Health Sciences

4

4

264

3

Natural Sciences

2

2

171

4

Education

1

1

14

5

Engineering

1

1

113

Xiaoyan Chu

×

64

Publications

4.1K

Citations

38

H-Index

YearCitations

Function and Expression of Multidrug Resistance-Associated Protein Family in Human Colon Adenocarcinoma Cells (Caco-2)

Tomoko Hirohashi, Hiroshi Suzuki, Xiaoyan Chu,

Journal of Pharmacology and Experimental Therapeutics

2000

192

Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics

Li Wang, Bhagwat Prasad, Laurent Salphati,

Drug Metabolism and Disposition

2014

187

Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

Xiaoyan Chu, Kelly Bleasby, Jocelyn Yabut,

Journal of Pharmacology and Experimental Therapeutics

2007

175

Multispecific Organic Anion Transporter Is Responsible for the Biliary Excretion of the Camptothecin Derivative Irinotecan and its Metabolites in Rats

Xiaoyan Chu, Yukio Kato, Kayoko Niinuma,

Journal of Pharmacology and Experimental Therapeutics

1997

163

Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide<scp>1B</scp>clinical probe than rosuvastatin

Thomayant Prueksaritanont, Xiaoyan Chu, Raymond Evers,

British Journal of Clinical Pharmacology

2014

162

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design

Marc L. Reitman, Xiaoyan Chu, Xiaoxin Cai,

Clinical Pharmacology & Therapeutics

2010

156

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk,

Drug Metabolism and Disposition

2013

147

Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)

Xiaoyan Chu, John R. Strauss, Michele A. Mariano,

Journal of Pharmacology and Experimental Therapeutics

2006

141

Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics

Bhagwat Prasad, Andrea Gaedigk, Marc Vrana,

Clinical Pharmacology & Therapeutics

2016

140

Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.

Xiaoyan Chu, Yukio Kato, Yuichi Sugiyama

PubMed

1997

131

Page 1